Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.
Botswana-Baylor Children's Clinical Centre of Excellence, Gaborone.
Gabriel
G
Anabwani
Department of Pediatrics, University Hospital Frankfurt, Goethe University, Germany.
Christoph
C
Königs
Department of Women's and Children's Health, University of Padua, Italy.
Carlos
C
Giaquinto
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.
Stella
S
Aslanyan
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.
John P
JP
Sabo
Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.
J-Scott
JS
Morrow
Department of Pediatric Pneumology and Immunology, Charité University Medicine, Berlin, Germany.
Cornelia
C
Feiterna-Sperling
D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring
D019380:Anti-HIV Agents; D003692:Delayed-Action Preparations; D019829:Nevirapine
HIV-1; extended-release formulation; long-term follow-up; nevirapine; pediatric patients